The PE firm Ampersand Capital Partners has acquired Pacific Biomarkers and is merging the CRO with Neomed-Labs to streamline clinical immunology development.
InvVax’s universal flu vaccine candidate has demonstrated preclinical success as the company prepares for a Phase I clinical trial, supported by a Series A fundraising round.
Velesco Pharma has expanded its analytical research and development capabilities to meet a growing demand for its services after acquiring a new facility in Michigan.
BioIVT will use its new internal cloud-based Quality Management System to manage clinical trial data at all of its locations, following the acquisition of five companies since 2017.
An additional investment at the PCI clinical services’ site brought forth an expansion to support the return of investigational drug products used in clinical trials.
DZS Clinical Services has been acquired by the global CRO WDMD in a deal that will expand its service offerings globally with the addition of coverage in Europe and Japan.
The Nuvisan Group is taking on part of Galderma’s R&D capacities site, growing its service lines in bioanalysis, clinical trial supplies, and pharmaceutical analytics
